Last reviewed · How we verify
NCT07354503
Telitacicept in the Treatment of Pediatric IgA Vasculitis-Associated Nephritis
trial testing Collect clinical data from the patients. in IgAVN in 300 participants. Not yet recruiting.
30 June 2027
Quick facts
| Lead sponsor | The Children's Hospital of Zhejiang University School of Medicine |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 January 2026 |
| Primary completion | 30 June 2027 |
| Estimated completion | 30 June 2028 |
Drugs / interventions tested
- Collect clinical data from the patients.
- This study exclusively prospectively collected clinical data from the patients and did not involve any therapeutic interventions
Conditions studied
- IgAVN — all drugs for IgAVN →
- IgA Vasculitis — all drugs for IgA Vasculitis →
Sponsor
The Children's Hospital of Zhejiang University School of Medicine
Who can join
Adults 3 to 17, any sex, with IgAVN or IgA Vasculitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To further evaluate the efficacy and safety of Telitacicept in the treatment of pediatric IgA vasculitis nephritis (IgAVN) within real-world settings, this study employs a multicenter, retrospective and prospective observational research design. It aims to compare the efficacy of Telitacicept with that of glucocorticoids, thereby providing clinicians with a reference for the rational and standardized application of Telitacicept.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07354503
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for IgAVN
Currently open trials in the same condition.
- NCT07024563 — Study of Ravulizumab in Pediatric Participants With Primary IgAN · Phase 3 · recruiting
Other The Children's Hospital of Zhejiang University School of Medicine trials
Trials by the same sponsor.
- NCT07368504 — AI for Newborn Metabolic Screening · NA · not yet recruiting
- NCT07499154 — Perioperative Lidocaine for Lung Protection in Infants Undergoing Cardiac Surgery · Phase 4 · not yet recruiting
- NCT07490041 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refr · EARLY_PHASE1 · recruiting
- NCT07496541 — Serum Copeptin as Biomarker for Diagnosis and Classification of Polyuric Primary Monosymptomatic Nocturnal Enuresis · not yet recruiting
- NCT07045844 — Effects of Enteral Feeding Regimens on NEC, Mortality, and Neurodevelopment in Very Preterm Infants · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07354503 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Children's Hospital of Zhejiang University School of Medicine
- Last refreshed: 21 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07354503.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing